Written by Private MD Labs Medical Writing Team • Last Updated: September 8, 2025
Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, are chronic conditions that cause inflammation in the digestive tract. While there isn't a single blood test that definitively diagnoses IBD, blood testing plays a fundamental role in assessing genetic risk factors, monitoring inflammation levels, and supporting the overall management of these conditions.
This genetic marker test identifies individuals who may have a higher risk of developing inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. The presence of the HLA-B27 antigen has been correlated with increased susceptibility to these conditions, making it valuable for risk assessment.
IBD diagnosis typically requires a combination of clinical evaluation, imaging studies, and endoscopic procedures. However, blood tests are essential for identifying genetic markers that may increase disease risk, measuring inflammatory activity, and monitoring the body's response to treatment over time.
This test measures lysozyme levels in the blood, which can become elevated during inflammatory responses. Increased lysozyme levels have been associated with inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, helping healthcare providers monitor disease activity and the body's inflammatory state.
These blood tests provide valuable information about genetic predisposition and inflammatory activity, but they must be interpreted alongside clinical symptoms and other diagnostic methods. Results help healthcare providers develop comprehensive treatment plans and monitor disease progression over time.
The information here is for educational purposes only and is not a substitute for professional medical advice. Always consult with a healthcare provider for diagnosis and treatment of inflammatory bowel diseases.